IoT-based Smart Agriculture Global Markets Report 2022 With Focus on Major Players - Topcon, Farmers Edge, Bayer AG and Yara - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "IoT-based Smart Agriculture: Global Markets" report has been added to ResearchAndMarkets.com's offering. The report provides an overview of the global market for IoT-base
Ocular Stock Rises as Eye Drug Implant OTX-TKI Shows Promise in Vision Disorder in Trial
Ocular Therapeutix (NASDAQ:OCUL) said its eye implant OTX-TKI was seen to be safe and well tolerated in patients as per interim 7-month data from a U.S. phase 1 trial to treat wet age-related macular
The Prostate Cancer Therapy Market Will Soar. Here Are the Companies That Could Benefit.
With the number of new prostate cancer cases rising in the US since 2014 according to the CDC, the market for therapies to treat the cancer is increasing.
Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio
NEW YORK, Sept. 19, 2022 /PRNewswire/ -- The male hypogonadism market has been segmented by type (Klinefelter syndrome, Kallmann syndrome, and pituitary disorders) and geography (North America, Europe, Asia, and Rest of World (ROW)).
POINT Biopharma Global Initiated at Buy at Truist on Prostate Cancer Candidate
Truist has initiated POINT Biopharma Global as a buy citing the potential of PNT2002, its prostate cancer therapy candidate in phase 3. The firm has a $22 price target (~161% upside based on Thursday'
Bayer Starts Executive Search to Replace CEO Baumann – Bloomberg
German conglomerate Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) has started an executive search to replace the company's current Chief Executive Officer Werner Baumann, signaling his early departure, Bloomberg
Regeneron Draws Upgrades After Data for High Dose Eylea
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) two pivotal trials evaluating aflibercept 8 mg with 12- and 16-week dosing regimens met the primary endpoints in diabetic macular edema (DME) and wet age-
Regeneron Says Pivotal Trials for Less Frequent Eylea Injections Reached Main Goals
Regeneron (NASDAQ:REGN) announced Thursday that its blockbuster eye medication Eylea reached the primary endpoints in two pivotal trials designed to investigate a less frequent dosing regimen in patie
Bayer in $40M Settlement Over Allegations Related to Three Drugs
German pharmaceutical company Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) and its subsidiaries have agreed to pay $40M to settle claims over the alleged use of kickbacks and false statements related to three dr